Open AccessA review of venous thromboembolism in COVID‐19: A clinical perspective
Author(s) -
Ozsu Savas,
Gunay Ersin,
Konstantinides Stavros V.
Publication year - 2021
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13330
Subject(s) - medicine , contraindication , covid-19 , venous thromboembolism , intensive care medicine , critically ill , venous thrombosis , incidence (geometry) , pulmonary embolism , disease , critical illness , thrombosis , infectious disease (medical specialty) , pathology , alternative medicine , outbreak , physics , optics
Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalized COVID‐19 patients should take pharmacological thromboprophylaxis if there is no contraindication. However, there is no consensus on this issue. In this review, we discussed all these approaches in a critical perspective.